What is Mosaic Laboratories?
Mosaic Laboratories operates as a premier provider of pre-clinical and clinical trial services, catering to the pharmaceutical and biotechnology industries. The company's core mission revolves around delivering exceptional quality in analytical services, offering expert guidance on study design, providing insightful result interpretation, and ensuring superior customer service. This commitment aims to substantially influence the advancement of patient therapies. The company's expertise spans critical areas such as Hypoxia Inducible Factor 1 Subunit Alpha (HIF1-alpha) research, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) analysis, and Nectin Cell Adhesion Molecule 2 (Nectin-2) studies, all of which are vital in understanding disease mechanisms and developing novel treatments.
How much funding has Mosaic Laboratories raised?
Mosaic Laboratories has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Mosaic Laboratories
PPP
Public-Private Partnership
What's next for Mosaic Laboratories?
The substantial late-stage financing positions Mosaic Laboratories for accelerated scaling and potential market expansion. This capital injection is expected to fuel further development of its service offerings, enhance its technological infrastructure, and potentially support strategic partnerships or acquisitions. The company's focus on critical biological pathways and its robust service model suggest a trajectory aimed at solidifying its role as a key enabler of drug discovery and development, ultimately impacting the future of patient care.
See full Mosaic Laboratories company page
